Antiemetics for reducing vomiting related to acute ... - Update Software
Antiemetics for reducing vomiting related to acute ... - Update Software
Antiemetics for reducing vomiting related to acute ... - Update Software
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Analysis 1.5. Comparison 1 Oral ondansetron (weight dependent dose) vs placebo, Outcome 5 Rate of<br />
intravenous rehydration (up <strong>to</strong> 72 hrs following discharge from the ED stay), best-worst case scenario.<br />
Review: <strong>Antiemetics</strong> <strong>for</strong> <strong>reducing</strong> <strong>vomiting</strong> <strong>related</strong> <strong>to</strong> <strong>acute</strong> gastroenteritis in children and adolescents<br />
Comparison: 1 Oral ondansetron (weight dependent dose) vs placebo<br />
Outcome: 5 Rate of intravenous rehydration (up <strong>to</strong> 72 hrs following discharge from the ED stay), best-worst case scenario<br />
Study or subgroup Ondansetron Placebo Risk Ratio Weight Risk Ratio<br />
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI<br />
Freedman 2006 26/107 39/103 46.3 % 0.64 [ 0.42, 0.97 ]<br />
Ramsook 2002 6/74 16/71 19.0 % 0.36 [ 0.15, 0.87 ]<br />
Roslund 2008 13/51 31/55 34.7 % 0.45 [ 0.27, 0.76 ]<br />
Total (95% CI) 232 229 100.0 % 0.52 [ 0.38, 0.71 ]<br />
Total events: 45 (Ondansetron), 86 (Placebo)<br />
Heterogeneity: Chi 2 = 1.92, df = 2 (P = 0.38); I 2 =0.0%<br />
Test <strong>for</strong> overall effect: Z = 4.16 (P = 0.000031)<br />
Test <strong>for</strong> subgroup differences: Not applicable<br />
0.01 0.1 1 10 100<br />
Favours ondansetron Favours placebo<br />
<strong>Antiemetics</strong> <strong>for</strong> <strong>reducing</strong> <strong>vomiting</strong> <strong>related</strong> <strong>to</strong> <strong>acute</strong> gastroenteritis in children and adolescents (Review)<br />
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.<br />
52
Change language